民生证券股份有限公司 关于成都圣诺生物科技股份有限公司 2024 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》等有关法律法规的规定，民生证券股份有限公司（以下简称"保荐机构"） 作为成都圣诺生物科技股份有限公司（以下简称"圣诺生物"或"公司"）首次 公开发行股票并在科创板上市的持续督导保荐机构，负责圣诺生物上市后的持续 督导工作，并出具本持续督导跟踪报告。 序号 工作情况 持续督导情况 1 建立健全并有效执行持续督导工作制度， 并针对具体的持续督导工作制定相应的 工作计划 保荐机构已建立健全并有效执行了持 续督导制度，并制定了相应的工作计 划 2 根据中国证监会相关规定，在持续督导工 作开始前，与上市公司或相关当事人签署 持续督导协议，明确双方在持续督导期间 的权利义务，并报上海证券交易所备案 保荐机构已与圣诺生物签订《保荐协 议》，该协议明确了双方在持续督导 期间的权利和义务，并报上海证券交 易所备案 3 通过日常沟通、定期回访、现场检查、尽 职调查等方式开展持续督导工作 保荐机构通过日常沟通、定期或不定 期回访、现场检查等方式，了解圣诺 生物业务情况，对 ...

Core Viewpoint - The article discusses the competitive landscape of the collagen market in China, highlighting the success of domestic brand Chuangfukang, which has maintained stable prices for 23 years despite technological advancements and market pressures [2][5][14]. Market Background - The collagen market is on the brink of a "second explosion," with projections indicating that by 2027, the overall market size in China will reach 173.8 billion yuan [3]. - The rise of recombinant collagen has significantly contributed to market growth, with domestic companies breaking international barriers in collagen technology [3][5]. - The article emphasizes the importance of scientific communication in addressing consumer skepticism regarding price increases in collagen products [5][24]. Technological Breakthroughs - Chuangfukang, under Chuang'er Biotechnology, has made significant advancements in collagen extraction technology, reducing costs from 2,000 to 7,000 yuan per gram for imported collagen to a fraction of that for domestic products [3][12][19]. - The company has achieved FDA certification for its raw materials and has expanded its market reach to Europe, the U.S., and South Korea [3][5]. Challenges in Communication - The article identifies three main issues in the scientific communication of collagen products: homogenized messaging, lack of cost transparency, and a disconnect in consumer understanding of the medical benefits of collagen [5][24]. - Chuangfukang's low profile in the market has hindered broader consumer awareness of its technological breakthroughs [5][24]. Marketing and Consumer Engagement - The collaboration with the advertising agency Shizhi Xiang aims to address consumer concerns about pricing and technology through direct dialogue and transparency [6][8][24]. - The marketing strategy focuses on establishing trust through third-party validation and addressing sensitive pricing issues directly [24][26]. Brand Positioning - Chuangfukang's commitment to not raising prices for over two decades reflects its philosophy of making technological innovations accessible to a broader audience [14][19]. - The brand has achieved a high customer loyalty rate, with a 50% repurchase rate, attributed to its competitive pricing and product quality [20][22]. Conclusion - The article concludes that Chuangfukang's journey exemplifies the potential of domestic brands to innovate and maintain ethical pricing in a competitive market, emphasizing the need for effective communication strategies to enhance consumer trust and brand image [24][28].

成都圣诺生物科技股份有限公司 2024 年年度股东大会会议资料 成都圣诺生物科技股份有限公司 2024 年年度股东大会会议资料 目录 | 2024 | 年年度股东大会会议议程 4 | | --- | --- | | 2024 | 年年度股东大会会议议案 6 | | 议案一 | 《关于<公司 2024 年度董事会工作报告>的议案》 6 | | 议案二 | 《关于<公司 2024 年度监事会工作报告>的议案》 14 | | 议案三 | 《关于<公司 2024 年年度报告及其摘要>的议案》 19 | | 议案四 | 《关于<公司 2024 年度财务决算报告及 2025 年度财务预算报告>的议案》 20 | | 议案五 | 《关于 2024 年度利润分配及资本公积转增股本方案及 2025 年中期分红规划的议案》 | | | 22 | | 议案六 | 《关于续聘公司 2025 年度财务审计及内控审计机构的议案》 23 | | 议案七 | 《关于公司 2025 年度董事薪酬的议案》 24 | | 议案八 | 《关于公司 2025 年度监事薪酬的议案》 25 | | 议案九 | 《关于预计 2025 年度日常关联交易额度的 ...

Core Viewpoint - The company, Saintno Biopharmaceuticals (688117), reported a mixed financial performance for 2024 and the first quarter of 2025, with significant growth in Q1 2025 driven by increased sales of specific products, while facing challenges in overall profitability due to rising R&D costs [2][6]. Financial Performance - In 2024, the company achieved operating revenue of 456.07 million yuan, a year-on-year increase of 4.84% [2] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 45.61 million yuan, a decrease of 24.24% year-on-year [2] - For Q1 2025, the company reported operating revenue of 184.34 million yuan, a significant year-on-year increase of 77.15% [2] - The net profit attributable to the parent company for Q1 2025 was 47.12 million yuan, reflecting a year-on-year increase of 186.06% [2] R&D Progress - The company has made advancements in several R&D projects, including the approval of various raw materials and the establishment of a joint research center with Zhejiang University [3][6] - In 2024, the company invested 50.46 million yuan in R&D, representing 11.06% of its operating revenue, which is a 45.05% increase compared to the previous year [2] Overseas Market Strategy - The company plans to enhance its overseas sales strategy by building a professional sales and marketing team to improve market expansion and brand development [4] - An investment agreement was signed with Africa Bio Chem Co. Ltd in Tanzania for 30 million yuan, acquiring a 22.78% stake to strengthen its overseas presence [4] Capacity Expansion - The company is actively advancing several capacity expansion projects, including a production line for polypeptide raw materials and a technology transformation project for formulations [5] - The production line project has entered the validation stage, and the company aims to meet the growing customer demand through these expansions [5] Market Sentiment - Recently, one institution has given a buy rating for the stock, indicating positive market sentiment [7] - The stock has seen a net inflow of 59.1 million yuan in financing over the past three months, suggesting increased investor interest [8]

Core Insights - The company focuses on the peptide sector, emphasizing an "innovative drugs first, generic drugs core" business model, aiming to be a leader in the domestic and international peptide market [1][4] - In 2024, the company achieved a revenue of 456.07 million yuan and a net profit of 50.02 million yuan, with significant increases in sales from raw materials and custom production [1] - The first quarter of 2025 saw a revenue of 184.34 million yuan, a year-on-year increase of 77.15%, and a net profit of 47.12 million yuan, up 186.06% compared to the previous year [1] R&D and Market Expansion - The company is accelerating its R&D pipeline to capture opportunities in diabetes, obesity, and cosmetic applications, with 25 projects currently under development [2] - In 2024, the company invested 50.46 million yuan in R&D, representing 11.06% of its revenue, with a focus on various peptide products [2] - The company aims to enhance its core technological competitiveness by optimizing its R&D platform and attracting industry talent [2] Capacity Expansion - The company is advancing its capacity expansion projects, including a new production line for peptide raw materials and a technology upgrade for formulation industrialization [3] - A contract worth up to 350 million yuan has been signed for the supply of GLP-1 peptide raw materials, indicating strong demand in the market [3] - The company is expected to benefit from a supply-demand imbalance in peptide raw materials, which is projected to last until at least 2026 [3] Strategic Focus - In 2025, the company plans to continue focusing on the peptide pharmaceutical industry, enhancing R&D innovation and internationalization efforts [4] - The company aims to strengthen its market presence in core raw materials and formulation products, leveraging its complete industrial chain advantages [4]

证券代码：688117 证券简称：圣诺生物 公告编号：2025-012 成都圣诺生物科技股份有限公司 关于作废 2023 年限制性股票激励计划部分已授予 尚未归属的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都圣诺生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第二十五次会议和第四届监事会第二十四次会议，审议通过 了《关于作废 2023 年限制性股票激励计划部分已授予尚未归属的限制性股票的 议案》。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）等 法律法规、规范性文件及《成都圣诺生物科技股份有限公司 2023 年限制性股票 激励计划（草案）》（以下简称"《激励计划（草案）》"）的有关规定及公司 2023 年第二次临时股东大会的授权，同意作废公司 2023 年限制性股票激励计划 （以下简称"本激励计划"）部分已授予尚未归属的限制性股票合计 653,982 股。现将有关事项说明如下： 一、本激励计划已履行的决策程序和信息披露情况 （六）2024 年 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-011 成都圣诺生物科技股份有限公司 关于提请股东大会授权董事会 2025 年度以简易程序向 特定对象发行股票并办理相关事宜的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《证券发行与承销管理办法》等法律法规和规范性文件的有关 规定，成都圣诺生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第二十五次会议，审议通过《关于提请股东大会授权董事会 2025 年以简易程序向特定对象发行股票并办理相关事宜的议案》，同意公司董 事会提请股东大会授权董事会决定向特定对象发行融资总额不超过人民币 3 亿 元且不超过最近一年末净资产 20%的股票，授权期限为 2024 年年度股东大会审 议通过之日起至 2025 年年度股东大会召开之日止。本议案尚需提交公司股东大 会审议。 一、具体内容 （一）本次发行证券的种类和数量 本次发行股票募集资金总额不超 ...

民生证券股份有限公司 关于成都圣诺生物科技股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为成都 圣诺生物科技股份有限公司（以下简称"圣诺生物"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上 海证券交易所科创板股票上市规则》等相关规定，对圣诺生物 2024 年度募集资 金的存放和实际使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 经中国证券监督管理委员会《关于同意成都圣诺生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕1497 号）同意注册，公司获准向 社会公众公开发行人民币普通股（A 股）20,000,000 股，每股面值人民币 1 元， 每股发行价为人民币 17.90 元，合计募集资金总额为人民币 358,000,000.00 元， 扣除发行费用 ...

上海君澜律师事务所 关于 成都圣诺生物科技股份有限公司 2023 年限制性股票激励计划 作废部分已授予尚未归属的限制性股票相关事项 之 法律意见书 二〇二五年四月 上海君澜律师事务所 法律意见书 法律意见书 致：成都圣诺生物科技股份有限公司 上海君澜律师事务所（以下简称"本所"）接受成都圣诺生物科技股份有 限公司（以下简称"公司"或"圣诺生物"）的委托，根据《上市公司股权激 励管理办法》（以下简称"《管理办法》"）《上海证券交易所科创板股票上 市规则》（以下简称"《上市规则》"）《科创板上市公司自律监管指南第 4 号—股权激励信息披露》（以下简称"《监管指南》"）《成都圣诺生物科技 股份有限公司 2023 年限制性股票激励计划》（以下简称"《激励计划》"或 "本次激励计划"）的规定，就圣诺生物本次激励计划作废部分已授予尚未归 属的限制性股票（以下简称"本次作废"）相关事项出具本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法 律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及 本法律意见书出具日以前已经发生或者存在的事实，严格 ...

目 录 | | | | 二、财务报表…………………………………………………………第 | 6—13 | 页 | | --- | --- | --- | | （一）合并资产负债表…………………………………………… | 第 | 6 页 | | （二）母公司资产负债表………………………………………… | 第 | 7 页 | | （三）合并利润表………………………………………………… | 第 | 8 页 | | （四）母公司利润表……………………………………………… | 第 | 9 页 | | （五）合并现金流量表……………………………………………第 | 10 | 页 | | （六）母公司现金流量表…………………………………………第 | 11 | 页 | | （七）合并所有者权益变动表……………………………………第 | 12 | 页 | | （八）母公司所有者权益变动表…………………………………第 | 13 | 页 | | 三、财务报表附注……………………………………………… 第 14—101 | | 页 | | 四、附件…………………………………………………………第 102—105 | | 页 | 审 计 报 告 天 ...